

3. (Amended) The composition according to claim 1, wherein the antihistamine is azelastine and/or levocabastine.

4. (Amended) The composition according to claim 1, wherein the pharmaceutically tolerable ester is loteprednol etabonate.

*write descrip for asthma only + method allergy*  
5. (Amended) A method for the treatment of disorders of the lower and/or upper airways and/or for the treatment of allergies, comprising administering to a patient in need thereof, an effective amount of loteprednol and at least one topically administrable <sup>sp dk</sup> antihistamine, optionally together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

6. (Amended) The method according to claim 5, wherein such administration is intranasally or intraocularly simultaneously, in succession or independently of one another.

*not typical*  
7. (Amended) The method according to claim 5, which is administered as an inhalable liquid or solid preparation. *in which the compo.*

8. (Amended) The method according to claim 5, which is administered orally.

9. (Amended) A method for the treatment and prophylaxis of airway disorders <sup>3</sup> and/or allergies, comprising administering to a patient in need thereof, an effective amount

A1  
of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine,  
wherein the loteprednol or a pharmaceutically tolerable ester thereof and the  
antihistamine(s) are mixed individually or together, optionally together with customary  
excipients or vehicles, and the mixture is in a suitable administration form.

---

A2  
11. (Amended) A method for the treatment of allergic rhinitis and  
rhinoconjunctivitis comprising administering to a patient in need thereof, a combination of  
loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for  
simultaneous, sequential or separate administration.

---